Meta-analysis of coagulation disbalances in COVID-19: 41 studies and 17601 patients

1 Polina Len¹, Gaukhar Iskakova^{1,#}, Zarina Sautbayeva^{1,#}, Aigul
2 Kussanova^{1,2,#}, Ainur T. Tauekelova³, Madina M. Sugralimova³, Anar S.
3 Dautbaeva³, Meruert M. Abdieva³, Eugene D. Ponomarev⁴, Alexander
4 Tikhonov¹, Makhabbat S. Bekbossynova^{3,*}, Natasha S. Barteneva^{1,5,6*}

5 ¹School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan

6 ²Core Facilities, Nazarbayev University, Nur-Sultan, Kazakhstan

7 ³National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan

8 ⁴School of Biomedical Sciences, Chinese University of Hong Kong, Shatin. Hong Kong

9 ⁵National Laboratory Astana, Nur-Sultan, Kazakhstan

10 ⁶Brigham and Women's Hospital, Harvard Medical School, Boston, USA

11 [#]These authors made an equal contribution in the study

12 ^{*}Joint senior authors

13

14 Keywords: COVID-19; coagulopathy; thrombosis; D-dimers; platelets; fibrinogen; immature

15 reticulated platelets; prothrombin time

16

17 **Abstract**

18 **Introduction.** Coagulation parameters are important determinants for COVID-19 infection.

19 We conducted meta-analysis to assess the early hemostatic parameters in retrospective
20 studies in association with severity of infection.

21 **Methods.** Ovid, PubMed, Web of Sciences, and Google Scholar were searched for research
22 articles that addressed clinical characteristics of COVID-19 patients and disease severity.
23 Results were filtered using exclusion and inclusion criteria and then pooled into a meta-
24 analysis to estimate the standardized mean difference with 95% CI for each of five
25 coagulation parameters (D-dimers, fibrinogen, prothrombin time, platelets count, activated
26 partial thromboplastin time). Two authors independently extracted data and assessed study
27 quality. To explore the heterogeneity and robustness of our fundings, sensitivity and
28 subgroup analyses were conducted. Publication bias was assessed with contour-enhanced
29 funnel plots and Egger test by linear regression.

30 **Results.** Overall, 41 original studies (17601 patients) on SARS-CoV2 were included. For the
31 two groups of patients, stratified by severity, we identified that D-dimers, fibrinogen,
32 activated partial thromboplastin time, and prothrombin time were significantly higher in the
33 severe group (SMD 0.6985 with 95%CI [0.5155; 0.8815]); SMD 0.661 with 95%CI [0.3387;
34 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD 0.284 with 95%CI [0.1472;
35 0.4208]). In contrast, PLT was significantly lower in patients with more severe cases of
36 COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Neither the analysis by the leave-
37 one-out method nor the influence diagnostic have identified studies that solely cause
38 significant change in the effect size estimates. Subgroup analysis showed no significant
39 difference between articles originated from different countries but revealed that severity
40 assessment criteria might have influence over estimated effect sizes for platelets and D-

41 dimers. Contour-enhanced funnel plots and the Egger test for D-dimers and fibrinogen
42 revealed significant asymmetry that might be a sign of publication bias.

43 **Conclusions.** The standard coagulation laboratory parameters with exception of platelets
44 counts are significantly elevated in patients with severe COVID-19. However, fibrinolysis
45 shutdown requires evaluation outside conventional coagulation tests and analysis of
46 additional specific markers related to clotting formation and PLT characteristics. We
47 hypothesize that a proportion and parameters of immature reticulated platelets may serve as
48 additional biomarkers for prediction of adverse events.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

1 Introduction

In less than two years of the outbreak, the COVID-19 pandemic took almost five million lives (John Hopkins, 2021). SARS-CoV-2 is the seventh member of the large coronavirus family capable of inducing human disease (Carsana et al., 2020). Viral respiratory infections, including severe respiratory acute syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 may induce coagulopathy and lead to intravascular thrombi and deposition of fibrinogen (Hwang et al., 2005; Yang et al., 2005; Goeijenbier et al., 2012; WHO MERS guidelines, 2013; Giannis et al., 2020).

The coagulation system is activated and dysregulated during COVID-19 infection; however, characteristics of COVID-19 associated coagulopathy are different from coagulation disorders (Iba et al., 2020). Evidence of abnormal COVID-19-associated coagulation parameters appeared already in early publications from Wuhan (Chen et al., 2020; Wang et al., 2020; Zhou et al., 2020) and was supported by further publications worldwide (rev. Levi et al., 2020; Iba et al., 2020). The reported hemostatic abnormalities with COVID-19 infection include increased D-dimers levels (Lippi et al., 2020; Demelo-Rodriguez et al., 2020), fibrinogen levels (Ranucci et al., 2020; Panigada et al., 2020), changes in the quantities and levels of activation of platelets (Yang et al., 2020; Lippi et al., 2020; Hottz et al., 2020; Althaus et al., 2021), elevated von Willebrand factor (Goshua et al., 2020; Doevelaar et al., 2021, rev. by Becker et al., 2021) and other coagulation parameters. Persistently elevated thrombocytic events, even with initiation of prophylactic anti-coagulation, suggest the presence of hypofibrinolysis in addition to detected hypercoagulability in COVID-19 (Creel-Bulos et al., 2021; Bachler et al., 2021). It is also consistent with results of thromboelastography (TEG) reported by Wright et al. (2020).

There is a need in early detection of elevated coagulation biomarkers to optimize risk stratification of patients with COVID-19. However, due to limitations of early pandemic

research with small study sizes and highly heterogeneous datasets it is still debated. The aim of the current study was to evaluate the validity of stratification based on early coagulation parameters provided by different clinical studies worldwide. We also aimed to use subgroup analysis to explore whether heterogeneity in results was in part explained by differences in patient subpopulations. Finally, the coagulation parameters of our own cohort were included in a systematic meta-analysis of published studies.

2 Materials and Methods

In this study, we aimed to identify the relationship between coagulation biomarkers taken at admission and severity of COVID-19 in adult (>18) patients by estimating the effect size of five laboratory coagulation tests: D-dimers, platelets, fibrinogen, activated partial thromboplastin time, and prothrombin time.

2.1 Search Strategy, Exclusion and Inclusion criteria

To broaden our search, we included Ovid, PubMed, Web of Sciences, and Google Scholar in the study. They were thoroughly scanned using the following keywords: SARS-CoV-2, COVID-19, coagulation, severity, characteristics, features, D-dimers, platelets, fibrinogen, cohort, observational, retrospective. First, satisfying search results were exported to an Excel table and duplicates were eliminated. Second, we conducted a preliminary review of retrieved articles' abstracts. Papers that focused on pregnant women, children, or specific age groups were avoided. Similarly, works that focused on the effect of medical treatment or patients with particular commodities were not included in the meta-analysis. We also excluded studies that compared mortality among groups of COVID-19 patients. Then, each publication was checked according to the inclusion criteria: sample size, severity assessment criteria, presence of at least one coagulation marker of interest expressed as a continuous variable. To be included, a study should have had more than 15 patients and divided them according to the

disease severity - WHO guidelines, ICU admission, disease aggravation, or need for oxygen therapy. Next, a list of biomarkers should have included at least some of the coagulation parameters: platelets count (PLT), D-dimers (DD), fibrinogen (FIB), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), Activated thrombin (AT), Factor VIII (FVIII), and Von Willebrand factor (vWF). Finally, the quality of selected articles was assessed with the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional studies. Questions 5, 6, 12, 13 were not applicable to selected studies due to their observational/retrospective nature; Question 8 was not applicable to studies with dichotomous exposure values, like ICU admission and need for oxygen therapy. Hence, studies with a quality score of less than five were excluded from the analysis. Search, and quality check were conducted independently by two authors. Disagreements were resolved during a joint discussion with a third author.

2.2 Data extraction

The primary goal was to retrieve from each article data about two groups of patients differing by disease severity: group size, stratification criteria, results of the laboratory tests. Apart from these, we kept a record of the country, hospital, and admission time in order to identify and exclude duplicate patients.

2.3 Cohort from the National Research Center for Cardiac Surgery

2.3.1 Participants and data collection

From a large cohort of 560 patients consecutively admitted from June 2020 to August 2021 due to coronavirus infection to the cardiology department of the NCJSC “National Research Center for Cardiac Surgery” (NRCCS), Nur-Sultan, Kazakhstan, we selected 451 patients with a confirmed diagnosis of COVID-19, aged ≥ 18 years, and those with the onset of the disease ≤ 21 days, all of whom were hospitalized for at least 24 hours with COVID-19. All

demographic, clinical, laboratory data were extracted from the electronic records of the NRCSC. Laboratory tests included PLT, PT, international normalized ratio, APTT, FIB, DD. Blood samples were collected at admission by the clinical team. Clotting tests were performed according to standard methods. For coagulation tests (PT, international normalized ratio, APTT, FIB), we used AVATUBE® with sodium citrate, and it was measured on Sysmex CS-2500 (Sysmex, Japan). Blood for DD was collected in AVATUBE® with sodium citrate, and D-dimers were quantified on Cobas® 6000. PLT counts were measured on Sysmex XS-500 (Sysmex, Japan) with blood collection performed in AVATUBE® with K2 EDTA. The confirmation of SARS-CoV-2 infection was done by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) assay on nose/throat swab or sputum samples using CFX96® Real-Time System (Bio-Rad Laboratories, Inc., USA).

2.3.2 Clinical assessment

The COVID-19 population was initially divided into four groups according to disease severity following local guidelines “Diagnosis and treatment of Covid-19 in Adults” (<http://www.rcrz.kz/index.php/ru/2017-03-12-10-51-13/klinicheskie-protokoly>) (**Suppl. File 1**). The study protocol was approved by the medical ethics committee of the National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan waiving the need for written informed consent due to the retrospective design.

2.4 Data analysis

2.4.1 Data transformation

All data analysis was performed in the RStudio 1.4.1717 with R version 4.1.0 (Integrated Development Environment for R. RStudio, PBC, USA). In the most of cases, results were reported as the first, second (median), and third quartiles, reflecting that original data was not normally distributed. The “estmeansd” package was used to convert median, interquartile range, minimum and maximum values to mean and standard deviation. The package

implements Box Cox transformation to normalize raw data prior to conversion. Then, Lou (2018) formulas for mean and Wan (2014) formulas for standard deviation are used. Since the criteria and number of groups differed from study to study, patients had to be regrouped into the more and less severe groups accordingly: severe/critical and mild/moderate, ICU admitted patients and outpatients/general ward patients, observed aggravation and recovery/stable, and need for oxygen therapy.

2.4.2 Meta-analysis

The “meta” and “metafor” packages were used for the meta-analysis. Heterogeneity was assessed using the I^2 , tau-squared, and prediction intervals. Following the recommendations of Veroniki (2016), Paule-Mandel (PM) tau-squared estimator and Q-Profile (QP) tau-squared confidence interval estimator were used in this meta-analysis. To account for different measurement scales and possible inaccuracy of the Graph Digitizer, the standardized mean difference (SMD), or Hedges g, based on the inverse-variance approach, was estimated. For datasets with high heterogeneity, the Knapp-Hartung adjusted random-effects model is implemented. In case of low heterogeneity, the fixed-effects model is applied.

2.4.3 Sensitivity and Subgroup analysis

We also performed several sensitivity analyses using the “dmetar” package. First, we recalculated the effect size using the leave-one-out method. Second, basic outliers, studies whose confidence intervals do not overlap with the pooled effect confidence interval, were removed. Third, we ran the diagnostic for influential cases with Graphic Display of Study Heterogeneity (GOSH) plots and excluded them from the meta-analysis. To further explore the heterogeneity of the data, we conducted subgroup analyses: based on grouping criteria and location.

2.5 Publication Bias

189 We used the counter-enhanced Funnel plots and Egger's test by linear regression to assess
190 the possibility for publication bias in selected studies.

191
192 **Figure 1.** Flow diagram illustrating the process of data collection.

194 3 Results

195 3.1 Results of the Web Search

196 The stepwise process of selection is depicted in Figure 1. Initially, there were 4056 papers
197 that matched search parameters. After the removal of duplicates and studies that did not meet
198 the exclusion criteria, only 195 unique studies remained. A more thorough review based on
199 the inclusion criteria has proven 125 studies to be unfitting. In addition to 70 that were left,

15 studies were extracted from the references lists of previously published meta-analyses and systematic reviews. Finally, we performed a quality check and removed duplicate patients, which resulted in 40 being included into the meta-analysis. Besides original articles, we have included data from the National Research Center for Cardiac Surgery located in Nur-Sultan, Kazakhstan. This data set included data from 451 patients with acute COVID-19.

3.2 Description of Selected Studies

Overall, this meta-analysis comprises 17601 patients from 40 research papers and the NRCSC. Of the total, 24 studies originated from China, while the rest included data from France, Germany, Italy, Mexico, Singapore, South Korea, Turkey, UK, and the USA. Most of the articles (23) reported division of patients according to the WHO guidelines. Out of the rest, 12 articles made groups based on the ICU admission, 3 focused on disease aggravation, and 3 on the need for oxygen therapy. This information is depicted in **Figure 2** in more detail.

Figure 2. Diagram depicting characteristics of selected studies: (A) number of publications per country, (B) number of patients per country, (C) number of publications per severity assessment criterion. The latter (C) indicates the total number of research articles to be 42 instead of 41 because one study reported two populations of patients admitted to the hospital at different periods.

3.3 Results of Meta-analysis

3.3.1 Pooled Effect Sizes

We collected data for five coagulation parameters: PLT, DD, FIB, APTT, and PT. In all cases, the heterogeneity was extremely high ($I^2 > 80\%$), so the Knapp-Hartung adjusted random-effects model was applied in all parts of the meta-analysis. DD, FIB, APTT, and PT were significantly higher in more severe cases (SMD 0.6985 with 95%CI [0.5155; 0.8815]; SMD 0.661 with 95%CI [0.3387; 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD 0.284 with 95%CI [0.1472; 0.4208]). In contrast, PLT was significantly lower in patients with severe cases of COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Forest plots for the meta-analyses are shown in **Figures 3-4**, and results are highlighted in **Table 1**.

A Platelets

B D-dimer

233

234 **Figure 3.** Forest plot of association between COVID-19 severity and platelets (A), D-dimers

235 (B).

A Fibrinogen

B Activated partial thromboplastin time

C Prothrombin time

Figure 4. Forest plots of the association between COVID-19 severity and: (A) fibrinogen, (B) activated partial thromboplastin time, (C) prothrombin time.

Table 1. Summary of the effect sizes for all coagulation parameters

Parameter	Effect Size				Heterogeneity		
	Pooled SMD	95% CI	t	p value	I ² (%)	tau-squared	p value
PLT	-0.1684	[-0.2826; -0.0542]	-3	0.0051	82.2	0.0743	<0.0001
DD	0.6985	[0.5155; 0.8815]	7.74	<0.0001	94.2	0.2636	<0.0001
FIB	0.661	[0.3387; 0.9833]	4.27	0.0003	90.4	0.4812	<0.0001
APTT	0.2683	[0.1357; 0.4009]	4.22	0.0004	82.8	0.0558	<0.0001
PT	0.284	[0.1472; 0.4208]	4.3	0.0003	80	0.0785	<0.0001

3.3.2 Sensitivity and Subgroup Analysis

Neither the analysis by the leave-one-out method nor the influence diagnostic has identified studies that solely cause a significant change in the effect size estimates. Removal of several outliers based on the pooled and individual confidence intervals allowed significant decrease in heterogeneity, yet it did not affect the interpretation of the results. Adjusted effect sizes and heterogeneity measurements are summarized in **Table 2**. All influence diagnostic plots, such as Baujat and leave-one-out plots, Cook's distance, Covariance Ratio, etc., are provided in the **Suppl. Figures 1-16** along with resulting Forest plots.

GOSH plots were built for all five models. K-means, DBSCAN, and Gaussian Mixture Model were implemented as clustering methods. This diagnostic was not applied on PLT and DD since they only have one cluster each (**Figure 5**); for FIB, APTT, and PT, on the other hand, we constructed the plots and identified several possible influential cases. Original GOSH plots for these parameters are given at **Suppl. Figures**. For fibrinogen, models that include studies by Fu et al. (2020) and Wang et al. (2020) tend to show higher heterogeneity and greater effect size (**Figure 6A-B**). For activated partial thromboplastin time, GOSH plot demonstrated that studies by J. Zhao et al. (2021), H. Zhang et al (2020), and Yu et al. (2020) increase model's heterogeneity and slightly pull the effect size to the left (**Figure 6C-E**).

GOSH plots of the prothrombin time effect size identified four studies, three of which (J. Zhao et al (2021), Cugno et al. (2021), and Zhou et al. (2021) pull effect size to the left (**Figure 6F-H**), and one (Bastug et al.) pulls effect size to the right (**Figure 6I**). We've excluded these studies and recalculated the pooled effect size for each parameter. Results are summarized in **Table 2**.

To explore the possible sources of heterogeneity and test the robustness of our data, we have conducted subgroup analyses based on articles' country of origin and criteria for severity stratification. Results are summarized in **Table 3**. Subgroup analysis showed no significant difference between articles originated from different countries but revealed that severity assessment criteria might have an influence on overestimated effect sizes for PLT and DD. High heterogeneity levels seem to be persistent over different subgroups. Being the only exception, values of APTT obtained from non-Chinese articles were less heterogenous - 47.1% compared to 84.7% in studies originated in China.

Figure 5. GOSH diagnostic for influential cases in meta-analysis models (A) - PLT, (B) - DD.

Figure 6. GOSH plots fixed for influential studies in meta-analysis models. (A-B) - fibrinogen; (C-E) - APTT; (F-I) - prothrombin time.

Table 2. Summary results of the sensitivity analysis

Coagulation Parameter		Effect Size				Heterogeneity		
		Pooled SMD	95% CI	t	p value	I ² (%)	tau-squared	Q test p-value
PLT	Original	-0.1684	[-0.2826; -0.0542]	-3	0.0051	82.2	0.0743	<0.0001
	Outliers removed	-0.1416	[-0.2419; -0.0412]	-2.9	0.0076	56.3	0.0287	0.0002
	Inf. Stud. removed	-	-	-	-	-	-	-
DD	Original	0.6985	[0.5155; 0.8815]	7.74	<0.0001	94.2	0.2636	<0.0001
	Outliers removed	0.621	[0.4860; 0.7560]	9.47	< 0.0001	70.2	0.073	< 0.0001
	Inf. Stud. removed	-	-	-	-	-	-	-
FIB	Original	0.661	[0.3387; 0.9833]	4.27	0.0003	90.4	0.4812	<0.0001
	Outliers removed	0.5889	[0.4141; 0.7638]	7.14	< 0.0001	85	0.0801	< 0.0001
	Inf. Stud. removed	0.4855	[0.3030; 0.6679]	5.57	< 0.0001	86.1	0.1175	< 0.0001
APTT	Original	0.2683	[0.1357; 0.4009]	4.22	0.0004	82.8	0.0558	<0.0001
	Outliers removed	0.348	[0.2450; 0.4518]	7.14	< 0.0001	38.6	0.0125	0.0532
	Inf. Stud. removed	0.3214	[0.2036; 0.4392]	5.73	< 0.0001	68.8	0.0326	<0.0001
PT	Original	0.284	[0.1472; 0.4208]	4.3	0.0003	80	0.0785	<0.0001
	Outliers removed	0.293	[0.2099; 0.3761]	7.44	< 0.0001	26.9	0.0064	0.1407

283 **Table 3.** Summary results of the subgroup analysis

		Inf. Stud. removed	0.283	[0.1336; 0.4325]	3.94	0.0008	81	0.0877	< 0.0001
		Effect Size			Heterogeneity				
Coag. Param.	Variable	Subgroups	k	SMD [95%CI]	I ² (%)	tau-squared	p-subgroup		
PLT	Location								0.2123
		China	19	-0.2256 [-0.3747; -0.0764]	84.6	0.0694			
		Other	15	-0.1384 [-0.3037; 0.0270]	73.60%	0.0765			
	Criteria								0.0263
		Guidelines	19	-0.1618 [-0.3319; 0.0082]	85.10	0.0983			
		ICU	9	-0.1188 [-0.3056; 0.0680]	70.60	0.0308			
		Aggravation	3	-0.0948 [-0.8750; 0.6854]	74.60	0.0682			
		Oxygen Therapy	3	-0.6834 [-1.4303; 0.0636]	0.00	0			
DD	Location								0.3596
		China	23	0.7618 [0.5089; 1.0148]	94.70	0.3043			
		Other	14	0.5992 [0.3204; 0.8780]	91.60	0.1964			
	Criteria								0.0041
		Guidelines	22	0.6349 [0.4248; 0.8450]	92.10	0.1903			
		ICU	12	0.9257 [0.5007; 1.3506]	96.70	0.4027			
		Aggravation	3	0.2526 [-0.2458; 0.7510]	54.60	0.0182			
FIB	Location								0.0813
		China	11	0.9393 [0.3154; 1.5632]	93.50	0.8093			
		Other	11	0.4162 [0.1757; 0.6567]	74.50	0.0937			
	Criteria								0.156
		Guidelines	13	0.8539 [0.3128; 1.3949]	92.60	0.7496			
		ICU	8	0.4510 [0.1690; 0.7330]	84.30	0.0814			
		Aggravation	1	0.3031 [0.0253; 0.5809]	-	-			
APTT	Location								0.8248
		China	13	0.2768 [0.0730; 0.4806]	88.30	0.0872			
		Other	8	0.2499 [0.0661; 0.4337]	47.10	0.0169			
	Criteria								0.359
		Guidelines	16	0.2629 [0.1019; 0.4240]	84.70	0.0636			
		ICU	4	0.3500 [-0.1307; 0.8306]	70.60	0.052			
		Aggravation	1	0.0714 [-0.2051; 0.3480]	-	-			

PT	Location						0.9249
	China	16	0.2886 [0.1188; 0.4584]	81.80	0.0751		
	Other	8	0.2745 [-0.0244; 0.5734]	78.30	0.1016		
	Criteria						0.6332
	Guidelines	18	0.2889 [0.1401; 0.4377]	79.00	0.0628		
	ICU	5	0.2992 [-0.2853; 0.8836]	87.6	0.1962		
	Aggravation	1	0.1407 [-0.1360; 0.4175]	-	-		

3.3.3 Publication Bias

Contour-enhanced funnel plots for five coagulation parameters are depicted in **Figure 7**, and the results of Egger's test are summarized in **Table 4**. Based on the linear regression results, significant asymmetry is observed in published studies that included results for PLT, DD (Intercept [p-value]: -1.297 [0.0336], 3.182 [0.0013]), and somewhat significant asymmetry was indicated for FIB (1.872 [0.0493]). While it is impossible to predict whether asymmetry is coming solely from publication bias, contour-enhanced funnel plots for DD and FIB (**Figure 6B-C**) show that the number of papers with insignificant findings is very small ($p > 0.1$). This may advocate for the presence of some publication bias. In contrast, **Figure 6A** illustrates that even though the funnel plot for PLT has some asymmetry, there are plenty of publications with insignificant SMDs, thus decreasing the possibility of publication bias.

To further explore the robustness of our findings, we have conducted several additional tests. As reported by Zwetsloot (2017) and his colleagues, plotting SMD against its standard error to assess the publication bias can result in distorted funnel plots, leading to false-positive conclusions. Since SMD is necessary for our analysis and cannot be substituted, we used a sample size-based precision estimate instead of the standard error $- 1/\sqrt{n}$. The resulting funnel plots (**Supplemental Figure 16**) showed no significant distortion.

Similar corrections were made to Egger's test: since standardized mean difference and standard error are not independent, we can expect the test to yield some false-positive results.

In our calculations, we used the corrected SE suggested by Pustejovsky and Rodgers (2019). Results are given in the **Supplemental Table 2**. The only model that was affected by this correction was FIB (intercept 2.142 with a p-value of 0.0526 compared to the initial 1.872 and 0.0493), indicating that previously concluded asymmetry might have been a false positive. Interpretation of results for other parameters remained the same.

Figure 7. Contour-enhanced funnel plots evaluating the presence of publication bias in the pool of articles that report association between COVID-19 severity and (A) platelets; (B) D-dimer; (C) fibrinogen; (D) activated partial thromboplastin time; (E) prothrombin time.

Table 4. Egger's test for publication bias

Parameter	Intercept	Confidence Interval	t	p-value
PLT	-1.297	[-2.44, -0.15]	-2.221	0.0336
DD	3.182	[1.39, 4.97]	3.489	0.0013
FIB	1.872	[0.12, 3.63]	2.093	0.0493
APTT	0.775	[-1.37, 2.92]	0.708	0.4874
PT	-0.436	[-2.49, 1.62]	-0.417	0.6811

314

315 4. Discussion

316 There is a need to identify early indicators of the risk of critical patients progressing to
317 ICU at COVID-19. Abnormal coagulation parameters, including DD and FIB levels, changes
318 in PLT, and PT, are observed in many patients with COVID-19 infection at admission (rev.
319 Levi et al., 2020; Iba et al., 2020). However, as discussed by different authors, these
320 indicators provide contradictory information regarding risk stratification and prognosis (Luo
321 et al., 2020; Tang et al., 2020; Ding et al., 2021). There are several previous meta-analysis
322 reviews researching abnormal coagulation and the severity of COVID-2019 infection. The
323 majority of analyzed studies were conducted at the beginning of the pandemic and examined
324 the Chinese population of patients (before April 2020 - Xiong et al., 2020; Lippi et al., 2020;
325 Zhang et al., 2020; Zhu et al., 2021; June 2020 -Di Minno et al., 2020). Through our meta-
326 analysis study, it was revealed that DD and FIB levels, APTC, and prothrombin time were
327 significantly higher in the severe group of COVID-19 patients. In contrast, PLT was
328 significantly lower in these patients. There was no evidence of effects across different
329 geographic subgroups, with the exception of APTT values.

330

4.1 Platelet changes

In this meta-analysis, we systematically analyze evidence for the utility of lowered PLT levels on admission in the relationship to the severity of infection. Platelets play a crucial role in the maintenance of hemostasis, contribute to thromboinflammatory processes (van der Meijden, Heemskerk, 2019) and at different stages of viral infection, changes in platelet production or destruction may result in coagulation imbalances leading to pro-thrombotic events or in platelet dysfunction and bleeding risks (Assinger, 2014), and increased activation of platelets (Hottz et al., 2020; Zaid et al., 2020; Althaus et al., 2021). Thrombocytopenia (platelet count $<150 \times 10^9/L$) seems to represent an important marker of COVID-19 severity (Qu et al., 2020; Yang et al., 2020; Lippi et al., 2020; Iba et al., 2020) and mortality outcome (Lippi et al., 2020; Yang et al., 2020). The reasons for a thrombocytopenia are multi-factorial, which may include early suppression of megakaryocytes production and damage in bone marrow and lungs, hemophagocytosis, immune destruction of platelets and other reasons. Significant thrombocytopenia in COVID-19 is less frequent than it was reported for the largest SARS-1 cohort (45%) (Lee et al., 2003). SARS-1 induced platelet depletion was related to direct infection of megakaryocytes and hematopoietic progenitors (rev. by Yang et al., 2005). However, almost half of patients presented thrombocytosis following initial thrombocytopenia during SARS epidemics in 2003 (Wong et al., 2003). Recently, a different trend in platelet changes in COVID-19 patients with immune thrombocytic purpura (ITP) was reported by Cruz-Benito et al. (2021). Secondary to SARS-CoV2 infection in ITP-patients generally develops early thrombocytosis (Cruz-Benito et al., 2020). Only a few cases of thrombocytosis (in children) were reported during SARS-CoV2 pandemics (Feld et al., 2020) as part of a multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C) (Yasuhara et al., 2020). It is possible that opposite PLT changes may reflect different phases of COVID-19 infection (Thachil et al., 2020) – acute and convalescent

phases, though the explanation has not been established yet. The reactive thrombocytosis that may occur during the convalescent phase requires time observation that would include a period preceding patient discharge. The increase of immature reticulated platelets reported recently in COVID-19 patients by different groups (Cohen et al., 2021; Welder et al., 2021) may play a role in the limiting of effectiveness of anti-platelet therapies (Guthikonda et al., 2007; Ibrahim et al., 2012; Armstrong et al., 2017). Change in platelets parameters (increased mean volume) (Lippi et al., 2021) and reactivity are suggested to be associated with a severe COVID-19 infection (Hottz et al., 2020; Yatim et al., 2021).

4.2 DD and FIB levels, and Thromboembolic complications

Concordant with other studies, we found DD and FIB levels significantly elevated in severe COVID-19 infection, though DD levels results may suffer from some publication bias as revealed by meta-regression analysis. It may be related to the variability of DD assays used in the different studies: they are not directly comparable due to the difference in the monoclonal antibodies used for tests (Olson et al., 2013; rev. Goodwin et al., 2017). As confirmed by autopsy results, the elevated DD levels can be associated with fibrin deposits within pulmonary extravascular space and alveoli (Fox et al., 2020), but they may be nonspecific to intravascular fibrin formation (Hunt et al., 2020). High DD levels, together with elevated neutrophils, were reported to be predictive factors of pulmonary embolism in COVID-19 patients (Thoreu et al., 2021). Thromboembolic complications related to COVID-19 are responsible for a substantial mortality rate (Lodigiani et al., 2020; Kunutsor, Laukannen, 2020; Piazza et al., 2020; Grillet et al., 2020). Whereas the highest burden of thromboembolism is associated with patients in the ICU (Helms et al., 2020; Llitjos et al., 2020; Klok et al., 2020), patients in non-ICU settings also bear a significant risk of these complications, especially VTE (venous thromboembolism) (Lodigiani et al., 2020; Spyropoulos et al., 2020), as well as pulmonary embolism (Thoreau et al., 2021). Klock and

colleagues (2020) report that in spite of thrombosis prophylaxis, a high incidence of thrombotic complications in ICU patients is comparable with patients from other groups with DIC (disseminated intravascular coagulation). Moreover, multiple studies describe cerebral venous thrombosis (CVT) associated with COVID-19 infection (Garaci et al., 2020; Baudar et al., 2020). DD and FIB levels are elevated in COVID-19 and in thromboembolism, and therefore as single tests are unspecific and unhelpful in the differentiation of these conditions. In part, it may be explained by the involvement in abnormal coagulation at COVID-19 of different systems, including endothelial cells, complement activation, and hypofibrinolysis resulting in changes undetected by routine tests (Holter et al., 2020; Cugno et al., 2021). The dysfunction of endothelial cells with COVID-19 may contribute to excess thrombin generation and fibrinolysis shutdown, which is associated with VTE, stroke and, renal failure (Wright et al., 2020). There are different suggestions for COVID-19 risk stratification related to changes in platelets and endothelial cells, such as increased proportion of immature reticulated platelet fraction (Cohen et al., 2021; Welder et al., 2021) or CECs (circulating endothelial cells) counts in the blood representing stressed cells detached from injured vessels, reported in various inflammatory and infective diseases, and are indicative of disease severity (Blann et al., 2006). They were significantly higher in COVID-19 patients admitted to the ICU and positively correlated with the length of hospital stay (Guervilly et al., 2020). This marker is related to SARS-CoV2 directly infecting primary endothelial cells (Monteil et al., 2020). Furthermore, there is some evidence of infection in endothelial cells in severe cases of COVID-19 (Varga et al., 2020), including the presence of coronavirus particles in the cytoplasm of endothelial cells on electron microscopy (Colmenero et al., 2020). Platelets activation and endothelial cell damage in COVID-19 patients are also resulting in elevated levels of extracellular vesicles (EVs) (Capellano et al., 2021) recently associated with severity of disease (Krishnamachary et al., 2021).

4.3 Fibrinolysis shutdown requires evaluation outside conventional coagulation parameters

Fibrinolysis shutdown is induced by severe COVID-19 infection (Tang et al., 2020; Wright et al., 2020; Collett et al., 2021) and is partly responsible for high DD and FIB levels. Some pathophysiological changes may contribute to high procoagulant conditions secondary to COVID-19 infection. Thus, low plasminogen levels (Correa et al., 2020), similar to plasminogen-related fibrinolysis observed at other viral infections such as influenza infection (Berri et al., 2013), may lead to a hypercoagulability state. A multiplexed analysis of inflammation-related gene expression (249 genes from nCounter Inflammation panel; NanoString Technologies, USA) revealed similarities between lung specimens in influenza and Covid-19 groups (Ackermann et al., 2020). Depression of fibrinolysis was reported not only in ICU patients with severe infection and clinical signs of thromboembolism (Wright et al., 2020), but also in the general unselected ICU cohort (Correa et al., 2020; Collett et al., 2020; Nougier et al., 2020). Viscoelastic testing (ROTEM, tissue-type plasminogen activator (tPA) ROTEM, TEG) and evaluation of clot formation by Clot Waveworm analysis have demonstrated a hypercoagulable state, characterized by increased clot stiffness and severely impaired fibrinolysis (Nougier et al., 2020; Collett et al., 2020; Panigada et al., 2020; Pavoni et al., 2020; Fan et al., 2021; Hulshof et al., 2021). Elevated routine coagulation parameters taken at admission may help with initial differentiation of severe and non-severe COVID-19 patient groups, but they do not provide information about fibrinolysis shutdown.

Although our findings were consistent across different geographic groups, they were tempered by significant heterogeneity. The DD, FIB, and PLT elevation trends speak about the necessity of investigating the potential of additional specific biomarkers for stratification of COVID-19 patients at risk for fibrinolytic shutdown and associated micro-and macro-vascular events. We suggest that thorough characterization of platelets including a proportion

of immature reticulated platelets and their size/mean volume parameters as well as a clot formation testing requires to evaluate a risk of thromboembolic events in COVID-19 patients groups.

5 Limitations of the study

Our findings should be interpreted with some limitations. Firstly, most of the included studies were either retrospective and observational by design, thus prone to recall or misclassification bias. Second, such studies often imply recruitment by convenience sampling, in which case the representativeness of a study is questioned. The random effects model was used due to the high heterogeneity of research. In the context of this meta-analysis, several different endpoints were allowed: severity guidelines, ICU admissions, oxygen therapy requirement, and disease aggravation. In an attempt to overcome this issue, we have conducted a subgroup analysis. Third, uncontrolled variables might also pose a limitation - both the disease severity and coagulation parameters can be affected by several potential confounding variables, such as comorbidities, age, etc. Some studies have reported their results in terms of quartiles or maximum and minimum values. The necessity to convert values could potentially influence the results. Although sensitivity and subgroup analyses were conducted, some residual heterogeneity may affect the interpretation of results. Finally, the underlying mechanisms of coagulation markers at COVID-19 still need to be investigated.

6 Conclusions

Our findings support using a combination of coagulation parameters for risk stratification of patients with COVID-19 infection at the time of admission. However, additional evaluation using clotting formation methods or combination with platelet-specific biomarkers requires. This information may help physicians triage patients with thromboembolism. An

important consideration is an intermediate and long follow-up of COVID-19 patients. We hypothesize that increase in platelets turnover towards immature reticulated forms contribute to hypercoagulability state at COVID-19 patients and their resistance to anti-platelet therapy. Future research should take in account change in platelet parameters and platelet fragmentation leading to elevated levels of extracellular vesicles.

7 Data availability Statement

Data are available by request from co-corresponding authors.

8 Conflict of Interest

The authors declare no conflict of interest.

9 Author Contributions

P.L. - conceptualization, methodology, formal analysis, investigation, data curation, writing original draft, G.I., Z.S., A.K. – methodology, data curation, formal analysis, investigation; A.T.T., M.M.S., A.S.D., M.M.A., M.S.B. - methodology, formal analysis, investigation, data curation of NRCSC cohort, writing a draft; E.D.P., A.T.- methodology; analysis; funding, N.S.B. - conceptualisation, methodology, formal analysis, investigation, data curation, writing a draft. M.S.B. and N.S.B.- supervision. All authors read and edit a final draft.

10 Acknowledgments

We are very grateful to Sadyk Khamitov and Aliya Sailybayeva from the Research Department of National Research Center for Cardiac Surgery for their excellent organizational help. N.S.B. and A.T. were supported by FDCRGP SSH2020028, and N.S.B. by OPCR2020018 grants from Nazarbayev University.

11 Abbreviations

APTT - activated partial thromboplastin time; CI - confidence interval; DD - D-dimer; DIC – disseminated intravascular coagulation; FIB - fibrinogen; GOSH - graphical display of study heterogeneity; ICU - intensive care unit; MERS-CoV - Middle East respiratory syndrome coronavirus (MERS-CoV); NRCSC - National Research Center for Cardiac Surgery; PLT - platelets; PT - prothrombin time; ROTEM – rotation thromboelastometry; SARS-CoV - severe respiratory acute syndrome coronavirus (SARS-CoV); SMD - standardized mean difference; tPA - tissue-type plasminogen activator; VTE - venous thromboembolism; vWF - von Willebrand factor.

12 References

Ackermann, M., Verleden, S.E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., et al. (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N. Engl. J. Med.* 383, 120-128. doi: 10.1056/NEJMoa2015432

Aloisio, E., Chibireva, M., Serafini, L., Pasqualetti, S.S.F., Dolci, A., Panteghini, M., et al. (2020). A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity. *Arch. Pathol. Lab. Med.* 144, 1457-1464. doi: 10.5858/arpa.2020-0389-sa

Althaus, K., Marini, I., Zlamal, J., Pelzl, L., Singh, A., Häberle, H., et al. (2021). Antibody-induced procoagulant platelets in severe COVID-19 infection. *Blood*. 137, 1061–1071. doi: 10.1182/blood.2020008762

Armstrong, P.C., Hofer, T., Knowles, R.B., Tucker, A.T., Hayman, M.A. et al. (2017) Newly formed reticulated platelets undermine pharmacokinetically short-lived antiplatelet

499 therapies. *Atherosclerosis, Thromb. Vascular Biol.* 37, 949-956.
500 doi.org/10.1161/ATVBAHA.116.308763

501 Assinger, A. (2014). Platelets and infection-an emerging role of platelets in viral infection.
502 *Front. Immunol.* 5, 649. doi: 10.3389/fimmu.2014.00649

503 Bastug, A., Bodur, H., Erdogan, S., Gokcinar, D., Kazancioglu, S., Deniz, B., et al. (2020).
504 Clinical and laboratory features of COVID-19: predictors of severe prognosis. *Int.*
505 *Immunopharmacol.* 88:106950. doi: 10.1016/j.intimp.2020.106950

506 Baudar, C., Duprez, T., Kassab, A., Miller, N., Rutgers, M.P. (2020). COVID-19 as
507 triggering co-factor for cortical cerebral venous thrombosis? *J Neuroradiol.* 2020, 30205–
508 302144. doi: 10.1016/j.neurad.2020.06.008

509 Bauer, W., Galtung, N., Neuwinger, N., Kaufner, L., Langer, E., Somasundaram, R., et al.
510 (2021). A matter of caution: coagulation parameters in COVID-19 do not differ from patients
511 with ruled-out SARS-CoV-2 infection in the emergency department. *TH Open.* 5, e43-e55.
512 doi: 10.1055/s-0040-1722612

513 Becker, R.C., Sexton, C., Smyth, S. (2021). COVID-19 and biomarkers of thrombosis: focus
514 on von Willebrand factor and extracellular vesicles. *J. Thromb. Thrombolysis.* 1-10. doi:
515 10.1007/s11239-021-02544-x

516 Bergantini, L., Bargagli, E., d'Alessandro, M., Refini, R., Cameli, P., Galasso, L., et al.
517 (2021). Prognostic bioindicators in severe COVID-19 patients. *Cytokine.* 141, 155455. doi:
518 10.1016/j.cyto.2021.155455

519 Berri, F., Rimmelzwaan, G.F., Hanss, M., Albina, E., Foucault-Grunenwald, M.L., Le, V.B.,
520 et al. (2013). Plasminogen controls inflammation and pathogenesis of influenza virus
521 infections via fibrinolysis. *PLoS Pathog.* 9, e1003229. doi: 10.1371/journal.ppat.1003229

522 Blann, A.D., Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., et al.
523 (2005). Circulating endothelial cells. *Thromb. Haemost.* 93, 228-235. doi: 10.1160/TH04-09-
524 0578

525 Cappellano, G., Raineri, D., Rolla, R., Giordano, M., Puricelli, C., Vilardo, B., et al. (2021)
526 Circulating platelet-derived extracellular vesicles are a hallmark of SARS-Cov-2 infection.
527 *Cells* 10, 85. 10.3390/cells10010085

528 Cen, Y., Chen, X., Shen, Y., Zhang, X., Lei, Y., Xu, C., et al. (2020). Risk factors for disease
529 progression in patients with mild to moderate coronavirus disease 2019 - a multi-centre
530 observational study. *Clin. Microbiol. Infect.* 26, 1242-1247. doi: 10.1016/j.cmi.2020.05.04

531 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020). Epidemiological and
532 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
533 descriptive study. *Lancet.* 395, 507-513. doi: 10.1016/S0140-6736(20)30211-7

534 Chen, N., Li, Y., Fan, H., Tian, A., Yuan, H., Jiang, Z., et al. (2020). Analysis of dynamic
535 disturbance in blood coagulation function of patients with coronavirus disease 2019: a
536 retrospective observational study. *Medicine.* 99, e22635. doi: 510
537 10.1097/MD.00000000000022635

538 Chen, Q., Zheng, Z., Zhang, C., Zhang, X., Wu, H., Wang, J., et al. (2020). Clinical
539 characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou,
540 Zhejiang, China. *Infection.* 48, 543–551. doi: 10.1007/s15010-020-01432-5

541 Chen, Z., Zhang, F., Hu, W., Chen, Q., Li, C., Wu, L., et al. (2021). Laboratory markers
542 associated with COVID-19 progression in patients with or without comorbidity: A
543 retrospective Study. *J. Clin. Lab. Anal.* 35, e23644. doi: 10.1002/jcla.23644

544 Cohen, A., Harari, E., Cipok, M., Laish-Farkash, A., Bryk, G., Yahud, E. et al. (2021).
545 Immature platelets in patients hospitalized with COVID-19. *J. Thromb. Thrombolysis* 51,
546 608-616. doi.org/10.1007/s11239-020-02290-6

547 Collett, L.W., Gluck, S., Strickland, R.M., Reddi, B.J. (2021). Evaluation of coagulation
548 status using viscoelastic testing in intensive care patients with coronavirus disease 2019
549 (Covid-2019): an observational point prevalence cohort study. *Austr. Crit. Care.* 34, 155-159.
550 doi: 10.1016/j.aucc.2020.07.003

551 Colmenero, I., Santonja, C., Alonso-Riano, M., Hernandez-Martin, A., Andina, D., Wiesner,
552 T., et al. (2020). SARS-CoV2 endothelial infection causes COVID-19 chilblains:
553 histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.
554 *Br. J. Dermatol.* 183, 729-737. doi: 10.1111/bjd.19327

555 Correa, T.D., Cordioli, R.L., Guerra, J.C.C., da Silva, B.C., Rodrigues, R.R., de Souza, G.M.,
556 et al. (2020). Coagulation profile of COVID-19 patients admitted to the ICU: exploratory
557 study. *PLoS ONE.* 15, e0243604. doi: 10.1371/journal.pone.0243604

558 Creel-Bulos, C., Auld, S.C., Caridi-Scheible, M., Barker, N.A., Friend, S., Gaddh, M., et al.
559 (2021). Fibrinolysis shutdown and a thrombosis in a COVID-19 ICU. *Shock.* 55, 316-320.
560 doi: 10.1097/SHK.000000000000163

561 Cruz-Benito, B., Rivas-Pollmar, M.I., Roman, M.T.A., Trelles-Martinez, R., Martin-Salces,
562 M., Lazaro-del Campo, P. et al. (2020). Paradoxical effect of SARS-CoV2 infection with
563 immune thrombocytopenia. *Br. J. Haematol.* 192, 973-977. doi: 10.1111/bjh.17077

564 Cugno, M., Meroni, P. L., Gualtierotti, R., Griffini, S., Grovetti, E., Torri, A., et al. (2021).
565 Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
566 *J. Autoimmun.* 116, 102560. doi: 10.1016/j.jaut.2020.102560

Demelo-Rodriguez, P., Cervilla-Munoz, E., Ordieres-Ortega, L., Parra-Virto, A., Toledano-Macias, M. et al. (2020). Influence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimers levels. *Thrombosis Res.* 192, 23-26. doi: 10.1016/j.thromres.2020.05.018

Di Micco, P., Russo, V., Carannante, N., Imparato, M., Cardillo, G., and Lodigiani, C. (2020). Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency department: an Italian cohort study. *J. Clin. Med.* 9, 4134. doi: 10.3390/jcm9124134

Di Minno, M.N.D., Calcaterra, I., Lupoli, R., Storino, A., Spedicato, G.A., Maniscalco, M. et al. (2020) Hemostatic changes in patients with COVID-19: a meta-analysis with meta-regressions. *J. Clin. Med.* 9, 2244; doi:10.3390/jcm9072244

Ding, R., Yang, Z., Huang, D., Wang, Y., Li, X., Zhou, X., et al. (2021). Identification of parameters in routine blood and coagulation tests related to the severity of COVID-19. *Int. J. Med. Sci.* 18, 1207–1215. doi: 10.7150/ijms.47494

Doevelaar, A. A., Bachmann, M., Hölzer, B., Seibert, F. S., Rohn, B. J., Bauer, F., et al. (2021). Von Willebrand factor multimer formation contributes to immunothrombosis in Coronavirus disease 2019. *Critical Care Med.* 49, e512-e520. doi: 10.1097/CCM.0000000000004918

Fan, B. E., Ng, J., Chan, S.S.W., Christopher, D., Tso, A.C.E., Ling, A.M. et al. (2021). COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. *J. Thromb. Thrombolysis* 51, 663-674. doi.org/10.1007/s11239-020-02318-x

588 Feld, L., Belfer, J., Kabra, R., Goenka, P., Rai, S., Moriarty, S., et al. (2020). A case series of
589 the 2019 novel coronavirus (SARS-CoV-2) in 3 febrile infants in New York. *Pediatrics*.146,
590 e20201056. doi: 10.1542/peds.2020-1056

591 Fox, S.E., Akmatbekov, A., Harbert, J.L., Li, G., Brown, J.Q., and Vander Heide, R.S.
592 (2020). Pulmonary and cardiac pathology in African American patients with COVID-19: an
593 autopsy series from New Orleans. *Lancet Respir. Med.* 8, 681–686. doi: 10.1016/S2213-
594 2600(20)30243-5

595 Fu, J., Kong, J., Wang, W., Wu, M., Yao, L., Wang, Z., et al. (2020). The Clinical
596 implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a
597 retrospective study in Suzhou China. *Thromb. Res.* 192, 3-8. doi:
598 10.1016/j.thromres.2020.05.006

599 Garaci, F., Di Giuliano, F., Picchi, E., Da Ros, V., and Floris, R. (2020). Venous cerebral
600 thrombosis in COVID-19 patient. *J. Neurol. Sci.* 414, 116871. doi:
601 10.1016/j.jns.2020.116871

602 Gerotziafas, G. T., Sergentanis, T. N., Voiriot, G., Lassel, L., Papageorgiou, C., Elabbadi, A.,
603 et al. (2020). Derivation and validation of a predictive score for disease worsening in patients
604 with COVID-19. *Thromb. Haemost.* 120, 1680-1690. doi: 10.1055/s-0040-1716544

605 Giannis, D., Ziogas, I.A., and Gianni, P. (2020). Coagulation disorders in coronavirus
606 infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *J. Clin.*
607 *Virol.* 127, 104362. doi: 10.1016/j.jcv.2020.104362

608 Goeijenbier, M., Van Wissen, M., Van De Weg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C.
609 M., et al. (2012). Review: viral infections and mechanisms of thrombosis and bleeding. *J.*
610 *Med. Virol.* 84, 1680-1696. doi: 10.1002/jmv.23354

611 Goodwin, A.J., Higgins, R.A., Moser, K.A., Smock, K.J., Chandler, V.L., Kottke-Marchant,
612 K., et al. (2017). Issues surrounding age-adjusted D-dimer cutoffs that practicing physicians
613 need to know when evaluating patients with suspected pulmonary embolism. *Ann. Intern.*
614 *Med.* 166, 361–364. doi: 10.7326/M16-2030

615 Goshua, G., Pine, A.B., Meizlish, M.L., Chang, C.-H., Zhang, H., Bahel, P. et al (2020).
616 Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre,
617 cross-sectional study. *Lancet Haematol.* 7, e575–e582. doi: 10.1016/S2352 3026(20)30216-7

618 Grillet, F., Behr, J., Calame, P., Aubry, S., and Delabrousse, E. (2020). Acute pulmonary
619 embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography.
620 *Radiology.* 23, 201544. doi: 10.1148/radiol.2020201544

621 Guervilly, C., Burtsey, S., Sabatier, F., Cauchois, R., Lano, G., Abdili, E., et al. (2020).
622 Circulating endothelial cells as a marker of endothelial injury in severe COVID-19. *J. Infect.*
623 *Dis.* 222, 1789-1793. doi: 10.1093/infdis/jiaa528

624 Guthikonda, S., Lev, E.I., Patel, R., DeLao, T., Bergeron, A.L., Dong, J.F., et al. (2007)
625 Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of
626 aspirin. *J. Thromb. Haemost.* 5, 490-496. doi:10.1111/j.1538-7836.2007.02387.x

627 Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., et al.
628 (2020). High risk of thrombosis in patients with severe SARS-CoV2-infection: a multicenter
629 prospective cohort study. *Intens. Care Med.* 46, 1089-1098. doi: 10.1007/s00134- 020-06062-
630 x

631 Higuera-de-la-Tijera, F., Servín-Caamaño, A., Reyes-Herrera, D., Flores-López, A., Robiou
632 Vivero, E., Martínez-Rivera, F., et al. (2021). The Age-AST-D Dimer (AAD) regression

633 model predicts severe COVID-19 disease. Dis. Markers. 2021:6658270. doi:
634 10.1155/2021/6658270

635 Holter, J.C., Pischke, S.E., de Boer, E., Lind, A., Jenum, S., Holten, A.R. et al. (2020).
636 Systemic complement activation is associated with respiratory failure in COVID-19 patients.
637 Proc. Natl. Acad. USA 117, 25018-25025

638 Hottz, E.D., Azevedo-Quintanilha, I.G., Palhinha, L., Teixeira, L., Barretto, E.A., Pao,
639 C.R.R. et al. (2020). Platelet activation and platelet-monocyte aggregate formation trigger
640 tissue factor expression in patients with severe COVID-19. Blood 136, 1330-1341.
641 <https://doi.org/10.1182/blood.2020007252>

642 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of
643 patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 10223. doi:
644 10.1016/s0140-6736(20)30183-5

645 Hulshof, A.-M., Brueggemann, R.A.G., Mulder, M.M.G., van de Berg, T.W., Sels, J.-W.
646 E.M., Olie, R.H. (2021) Serial EXTEM, FIBTEM, and tPA Rotational thromboelastometry
647 observations in the Maastricht Intensive Care COVID Cohort – persistence of
648 hypercoagulability and hypofibrinolysis despite anticoagulation. Front. Cardiovasc. Med. 8,
649 654174. doi: 10.3389/fcvm.2021.654174

650 Hunt, B.J., Levi, M. (2020). The source of elevated plasma D-dimer levels in COVID-19
651 infection. Br. J. Haematol. doi: 10.1111/bjh.16907

652 Hwang, D. M., Chamberlain, D. W., Poutanen, S. M., Low, D. E., Asa, S. L., and Butany, J.
653 (2005). Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern.
654 Pathol. 18, 1–10. doi: 10.1038/modpathol.3800247

655 Iba, T., Levy, J.H., Levi, M., Connors, J.M., and Thachil, J. (2020). Coagulopathy of
656 coronavirus disease-2019. Crit. Care. Med. 48, 1358-1364. doi:
657 10.1097/CCM.0000000000004458

658 Ibrahim, H., Nadipalli, S., DeLao, T., Guthikonda, S., Kleiman, N.S. (2012) Immature
659 platelet fraction (IPF) determined with an automated method predicts clopidogrel
660 hyporesponsiveness. J. Thromb. Thrombolysis 33, 137–42. doi:10.1007/s11239-011-0665-7.

661 Johns Hopkins University & Medicine (2021). The Johns Hopkins Coronavirus Resource
662 Center (CRC). <https://coronavirus.jhu.edu/> [Accessed September 30, 2021].

663 Karakoyun, I., Colak, A., Turken, M., Altin, Z., Arslan, F. D., Iyilikci, V., et al. (2021).
664 Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in
665 hospitalized severe COVID-19 patients. Int. Immunopharmacol. 91, 107285. doi:
666 10.1016/j.intimp.2020.107285

667 Klok, F.A., Kruip, M.J.H.A., Van der Meer, N.J.M., Arbous, M.C., Gommers, D.A.M.P.J. et
668 al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-
669 19. Thrombosis Res. 191, 145-147. doi: 10.1016/j.thromres.2020.04.013

670 Krishnamachary, B., Cook, S., Kumar, A., Spikes, L., Chalise, P., Dhillon, N.K. (2021)
671 Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate
672 with COVID-19 disease severity. J. Extracel. Vesicles. 10, e12117. doi: 10.1002/jev2.12117

673 Kunutsor, S.K., and Laukkanen, J.A. (2020). Incidence of venous and arterial
674 thromboembolic complications in COVID-19: a systematic review and meta-analysis.
675 Thrombosis Res. 196, 27-30. doi: 10.1016/j.thromres.2020.08.022

676 Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G.M., et al. (2003). A major outbreak
677 of severe acute respiratory syndrome in Hong Kong. *N. Engl. J. Med.* 348, 1986–94.
678 <https://doi.org/10.1056/NEJMoa030685>

679 Levi, M., and Scully, M. (2018). How I treat disseminated intravascular coagulation. *Blood.*
680 131, 845-854. doi: 10.1182/blood-2017-10-804096

681 Levi, M., Thachil, J., Iba, T., Levi, J.H. (2020). Coagulation abnormalities and thrombosis in
682 patients with COVID-19. *Lancet Haematol.* 7, e438-440. doi: 10.1016/ S2352-
683 3026(20)30145-9

684 Liao, D., Zhou, F., Luo, L., Xu, M., Wang, H., Xia, J., et al. (2020). Haematological
685 characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a
686 retrospective cohort study. *Lancet Haematol.* 7, e671-e678. doi: 10.1016/s2352-
687 3026(20)30217-9

688 Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe
689 coronavirus disease 2019 (COVID-19) infections: a meta-analysis. *Clin. Chim. Acta* 506,
690 145–148. doi:10.1016/j. cca.2020.03.022

691 Lippi, G., Henry, B.M., Favaloro, E.J. (2021). Mean platelet volume predicts severe COVID-
692 19 illness. *Semin. Thromb. Hemost.* 47, 456-459
693 DOI: 10.1055/s-0041-1727283

694 Liu, J., Liu, Z., Jiang, W., Wang, J., Zhu, M., Song, J., et al. (2020a). Clinical predictors of
695 COVID-19 disease progression and death: analysis of 214 hospitalized patients from Wuhan,
696 China. *Clin. Res. J.* 15, 293-309. doi: 10.1111/crj.13296

697 Liu, J., Zhang, S., Wu, Z., Shang, Y., Dong, X., Li, G., et al. (2020b). Clinical outcomes of
698 COVID-19 in Wuhan, China: a large cohort study. *Ann. Intensive Care.* 10, 1-21. doi:
699 10.1186/s13613-020-00706-3

700 Liu, J., Tu, C., Zhu, M., Wang, J., Yang, C., Liu, W., and Xiong, B. (2021). The Clinical
701 course and prognostic factors of severe COVID-19 in Wuhan, China. *Medicine.* 100: e23996.
702 doi: 10.1097/md.00000000000023996

703 Liu, W., Tao, Z. W., Wang, L., Yuan, M. L., Liu, K., Zhou, L., et al. (2020). Analysis of
704 factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus
705 disease. *Chin. Med. J.* 133, 1032–1038. doi: 10.1097/cm9.0000000000000775

706 Llitjos, J.-F., Leclerc, M., Chochois, C., Monsallier, J.-M., Ramakers, M., Auvray, M., et al.
707 (2020). High incidence of venous thromboembolic events in anticoagulated severe COVID-
708 19 patients. *J. Thromb. Haemost.* 18, 1743-1746. doi: 10.1111/jth.14869

709 Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T.,
710 et al. (2020). Venous and arterial thromboembolic complications in COVID-19 patients
711 admitted to an academic hospital in Milan, Italy. *Thromb. Res.* 191, 9–14. doi:
712 10.1016/j.thromres.2020.04.024

713 Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X., et al. (2020). D-Dimer and
714 prothrombin time are the significant indicators of severe COVID-19 and poor prognosis.
715 *Biomed. Res. Int.* 2020, 6159720. doi: 10.1155/2020/6159720

716 Lopez-Castaneda, S., García-Larragoiti, N., Cano-Mendez, A., Blancas-Ayala, K., Damian-
717 Vázquez, G., Perez-Medina, A. I., et al. (2021). Inflammatory and prothrombotic biomarkers
718 associated with the severity of COVID-19 infection. *Clin. Appl. Thromb. Hemost.* 27, 1-9.
719 doi: 10.1177/1076029621999099

720 Luo, D., Wan, X., Liu, J., and Tong, T. (2018). Optimally estimating the sample mean from
721 the sample size, median, mid-range, and/or mid-quartile range. *Stat. Meth. Med. Res.* 27,
722 1785–1805. doi: 10.1177/0962280216669183

723 Luo, L., Xu, M., Du, M., Kou, H., Liao, D., Cheng, Z., et al. (2020). Early coagulation tests
724 predict risk stratification and prognosis of COVID-19. *Aging (Albany NY)*. 12, 15918-
725 15937. doi: 10.18632/aging.103581

726 Mikami, T., Miyashita, H., Yamada, T., Harrington, M., Steinberg, D., Dunn, A., and Siau, E.
727 (2021). Risk factors for mortality in patients with COVID-19 in New York City. *J. Gen.*
728 *Intern. Med.* 36, 17-26. doi: 10.1007/s11606-020-05983-z

729 Monteil, V., Kwon, H., Prado, P., Hagelkruys, A., Wimmer, R. A., Stahl, M., et al. (2020).
730 Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade
731 soluble human ACE2. *Cell* 181, 905-913. doi: 10.1016/j.cell.2020.04.004

732 National Heart, Lung, and Blood Institute. (2019). Study quality assessment tools.
733 [https://www. nhlbi. nih. gov/health-topics/study-quality-assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools) [Accessed
734 September 20th, 2021].

735 Noh, C. S., Kim, W. Y., and Baek, M. S. (2021). Risk factors associated with the need for
736 oxygen therapy in patients with COVID-19. *Medicine*. 100, e25819. doi:
737 10.1097/md.00000000000025819

738 Nougier, C., Benoit, R., Simon, M., Desmurs-Clavel, H., Marcotte, G., Argaud, L., et al.
739 (2020) Hypofibrinolytic state and high thrombin generation may play a major role in SARS-
740 Cov2 associated thrombosis. *J. Thromb. Haemost.* 18, 2215-2219. doi: 10.1111/jth.15016

741 Olson, J.D., Cunningham, M.T., Higgins, R.A., Eby, C.S., and Brandt, J.T. (2013). D-dimer:
742 simple test, tough problems. Arch. Pathol. Lab. Med. 137, 1030-1038.
743 doi:10.5858/arpa.2012-0296-CP

744 Panigada, M., Bottino, N., Tagliabue, P., Grasselli, G., Novembrino, C., Chantarangkul, V.,
745 et al. (2020). Hypercoagulability of COVID-19 patients in intensive care unit: a report of
746 thromboelastography and other parameters of hemostasis. J. Thromb. Haemost. 18, 1738-
747 1742. doi: 10.1111/jth.14850

748 Pavoni, V., Ganesello, L., Pazzi, M., Stera, C., Meconi, T., Frigieri, F.C. (2020) Evaluation
749 of coagulation function by rotation thromboelastometry in critically ill patients with severe
750 COVID-19 pneumonia. J. Thromb. Thrombolysis. 50, 281-286. doi: 10.1007/s11239-020-
751 02130-7

752 Piazza, G., Campia, U., Hurwitz, S., Snyder, J. E., Rizzo, S. M., Pfeferman, M. B., et al.
753 (2020). Registry of arterial and venous thromboembolic complications in patients with
754 COVID-19. J. Am. Coll. Cardiol. 76, 2060-2072. doi: 10.1016/j.jacc.2020.08.070

755 Pustejovsky, M.A., and Rodgers, J.E. (2019). Testing for funnel plot asymmetry of
756 standardized mean differences. Res. Synthesis Meth. 10, 57-71. doi: 10.1002/jrsm.1332

757 Qu, R., Ling, Y., Zhang, Y.H.Z., Wei, L.Y., Chen, X., Li, X.M. et al. (2020). Platelet-to
758 lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J. Med.
759 Virol. 92, 1533-1541. doi: 10.1002/jmv.25767

760 Ranucci, M., Ballotta, A., Di Dedda, U., Bayshnikova, E., Dei Poli, M., Resta, M., et al.
761 (2020). The procoagulant pattern of patients with COVID-19 acute distress syndrome. J.
762 Thromb. Haemost. 18, 1747-1751. doi: 10.1111/jth.14854

763 Rauch, A., Labreuche, J., Lassalle, F., Goutay, J., Caplan, M., Charbonnier, L., et al. (2020).
764 Coagulation biomarkers are independent predictors of increased oxygen requirements in
765 COVID-19. *J. Thromb. Haemost.* 18, 2942-2953. doi: 10.1111/jth.15067

766 Shang, W., Dong, J., Ren, Y., Tian, M., Li, W., Hu, J., et al. (2020). The value of clinical
767 parameters in predicting the severity of COVID-19. *J. Med. Virol.* 92, 2188-2192. doi:
768 10.1002/jmv.26031

769 Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., et al. (2020).
770 Scientific and standardization committee communication: clinical guidance on the diagnosis,
771 prevention and treatment of venous thromboembolism in hospitalized patients with COVID-
772 19. *J. Thromb. Haemost.* 18, 1859–1865. doi: 10.1111/jth.14929

773 Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., et al.
774 (2020). Clinical characteristics and morbidity associated with coronavirus disease-2019 in a
775 series of patients in metropolitan Detroit. *JAMA Netw. Open.* 3, e2012270. doi: 715
776 10.1001/jamanetworkopen.2020.12270

777 Tang, N., Li, D., Wang, X., and Sun, Z. (2020). Abnormal coagulation parameters are
778 associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb.*
779 *Haemost.* 18, 844-847. doi: 10.1111/jth.14768

780 Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., et al. (2020). ISTH
781 interim guidance on recognition and management of coagulopathy in COVID-19. *J. Thromb.*
782 *Haemost.* 18, 1023-1026. doi: 10.1111/jth.14810

783 Thoreau, B., Galland, J., Delrue, M., Neuwirth, M., Stepanian, A., Chauvin, A. et al. (2021).
784 D-Dimer levels and neutrophils count as predictive and prognostic factors of pulmonary

785 embolism in severe non-ICU COVID-19 patients. *Viruses*. 13, 758. doi: 725
786 10.3390/v13050758

787 Van der Meijden, P.E.J., Heemskerk, J.W.M. (2019) Platelet biology and functions: new
788 concepts and clinical perspectives. *Nature Rev. Cardiol.* 16, 166-179.
789 <https://doi.org/10.1038/s41569-018-0110-0>

790 Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., et
791 al. (2020). Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 395, 1417–1418.
792 doi: 10.1016/S0140-6736(20)30937-5

793 Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., et al.
794 (2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis.
795 *Res. Synth. Methods*. 7, 55–79. doi: 10.1002/jrsm.1164

796 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical characteristics of
797 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
798 *JAMA*. 323, 1061-1069. doi: 10.1001/jama.2020.1585

799 Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the Sample Mean and Standard
800 Deviation from the Sample Size, Median, Range and/or Interquartile range. *BMC Med. Res.*
801 *Methodol.* 14, 1-13. doi: 10.1186/1471-2288-14-135

802 Wang, P., Sha, J., Meng, M., Wang, C., Yao, Q., Zhang, Z., et al. (2020). Risk factors for
803 severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective
804 study. *J. Transl. Med.* 18, 1-12. doi: 10.1186/s12967-020-02655-8

805 Wang, Y., Yao, L., Zhang, J. P., Tang, P. J., Ye, Z. J., Shen, X. H., et al. (2020). Clinical
806 characteristics and laboratory indicator analysis of 67 COVID-19 pneumonia patients in
807 Suzhou, China. *BMC Infect. Dis.* 20,747. doi: 10.1186/s12879-020-05468-8

808 Welder, D., Jeon-Slaughter, H., Ashraf, B., Choi, S.-H., Chen, W., Ibrahim, I. et al. (2021).
809 Immature platelets as a biomarker for disease severity and mortality in COVID-19 patients.
810 Br. J. Haem. 194, 530-536. <https://doi.org/10.1111/bjh.17656>

811 White, D., MacDonald, S., Edwards, T., Bridgeman, C., Hayman, M., Sharp, M., et al.
812 (2020). Evaluation of COVID-19 coagulopathy: laboratory characterization using thrombin
813 generation and nonconventional haemostasis assays. Int. J. Lab. Hematol. 43, 123-130. doi:
814 10.1111/ijlh.13329

815 Wong, R.S., Wu, A., To, K.F., Lee, N, Lam, C.W., Wong, C.K., et al. (2003).
816 Haematological manifestations in patients with severe acute respiratory syndrome:
817 retrospective analysis. Br. Med. J. 326, 1358– 62.

818 World Health Organization. (2013). Guidelines for investigation of cases of human infection
819 with Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
820 (https://cdn.who.int/media/docs/default-source/documents/emergencies/health-topics---mers/mers_cov_investigation_guideline_jul132d7b61a0-a593-4527-8246-25152b965baf.pdf?sfvrsn=3e2f6c65_1&download=true) [Accessed September 30, 2021]

823 Wright, F.L., Vogler, T.O., Moore, E.E., Moore, H.B., Wohlauser, M.V., Urban, S., et al.
824 (2020). Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19
825 infection. J. Amer. Col. Surgeons. 231, 193-203. doi: 10.1016/j.jamcollsurg.2020.05.007

826 Xiong, M., Liang, X., and Wei Y.D. (2020). Changes in blood coagulation in patients with
827 severe coronavirus disease 2019 (COVID-2019): a meta-analysis. Br. J. Haem. 189, 1050-
828 1052. doi: 10.1111/bjh.16725

829 Yang, M., Ng, M. H., and Li, C. K. (2005). Thrombocytopenia in patients with severe acute
830 respiratory syndrome. Hematology 10, 101–105. doi: 10.1080/10245330400026170

831 Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., et al. (2020). Thrombocytopenia and
832 its association with mortality in patients with COVID-19. *J. Thromb. Haemost.* 18, 1469–72.
833 doi: 10.1111/jth.14848

834 Yasuhara, J., Kuno, T., Takagi, H., and Sumitomo, N. (2020). Clinical characteristics of
835 COVID 19 in children: a systematic review. *Pediatr. Pulmonol.* 55, 2565-2575. doi:
836 10.1002/ppul.24991

837 Yatim, N., Boussier, J., Chocron, R., Hadjadj, J., Philippe, A., Gendron, N. (2021). Platelet
838 activation in critically ill COVID-19 patients. *Ann. Intensive Care* 11, 113.
839 doi.org/10.1186/s13613-021-00899-1

840 Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., et al. (2020).
841 Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in
842 Singapore. *JAMA* 323, 1488-1494. doi: 10.1001/jama.2020.3204

843 Yu, C., Lei, Q., Li, W., Wang, X., Li, W., and Liu, W. (2020). Epidemiological and clinical
844 characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a
845 single-center experience. *J. Infect. Public Health.* 13, 1202–1209. doi:
846 10.1016/j.jiph.2020.07.002

847 Yue, T., Zhou, W., He, J., Wang, H., Liu, Y., Wang, B., et al. (2021). Combined clinical and
848 imaging features better predict the critical outcomes of patients with SARS-COV-2. *Medicine*
849 100, e25083. doi: 10.1097/md.00000000000025083

850 Zhang, A., Leng, Y., Zhang, Y., Wu, K., Ji, Y., Lei, S., et al. (2020). Meta-analysis of
851 coagulation parameters associated with disease severity and poor prognosis of COVID-19.
852 *Inter. J. Infect. Dis.* 100, 441-448. doi: 10.1016/j.ijid.2020.09.021

853 Zhang, H., Wang, X., Fu, Z., Luo, M., Zhang, Z., Zhang, K., et al. (2020). Potential factors
854 for prediction of disease severity of COVID-19 patients. medRxiv [Preprint]. doi:
855 10.1101/2020.03.20.20039818

856 Zhang, J., Huang, X., Ding, D., and Tao, Z. (2021). Platelet-driven coagulopathy in COVID-
857 19 patients: in comparison to seasonal influenza cases. Exp. Hematol. Oncol. 10, 1-13. doi:
858 10.1186/s40164-021-00228-z

859 Zhao, J., Zhu, M., Su, X., Huang, M., Yang, Y., Huang, J., et al. (2021). Clinical features and
860 risk factors for severe-critically ill COVID-19 adult patients in Jiangsu, China. Medicine.
861 100, e24332. doi: 10.1097/md.00000000000024332

862 Zhao, Y., Yu, C., Ni, W., Shen, H., Qiu, M., and Zhao, Y. (2021). Peripheral blood
863 inflammatory markers in predicting prognosis in patients with COVID-19. Some differences
864 with Influenza A. J. Clin. Lab. Anal. 35, e23657. doi: 10.1002/jcla.23657

865 Zheng, X., Chen, J., Deng, L., Fang, Z., Chen, G., Ye, D., et al. (2020). Risk factors for the
866 COVID-19 severity and its correlation with viral shedding: a retrospective cohort study. Int.
867 J. Infect. Dis. 93, 952-961. doi: 10.1002/jmv.26367

868 Zhou, C., Huang, Z., Tan, W., Li, X., Yin, W., Xiao, Y., et al. (2020). Predictive factors of
869 severe coronavirus disease-2019 in previously healthy young adults: a single-center,
870 retrospective study. Respir. Res. 21:157, 1-8. doi: 10.1186/s12931-020-01412-1

871 Zhu, J., Pang, J., Ji, P., Zhong, Z., Li, H., Li, B. et al. (2020) Coagulation dysfunction is
872 associated with a severity of COVID-19. J. Med. Virol. 93, 962-972. doi: 10.1002/jmv.26336

873 Zwetsloot, P.-P., Naald, M.V.D., Sena, E.S., Howells, W.D., IntHout, J., De Groot, J.A.H. et
874 al. (2017). Standardized means differences cause funnel plots distortion in publication bias
875 assessments. eLife 6, e24260 DOI: 10.7554/eLife.24260

Legends to the Tables

Table 1. Summary of the effect sizes for all coagulation parameters

Table 2. Summary results of the sensitivity analysis

Table 3. Summary results of the subgroup analysis

Table 4. Egger's test for publication bias

Legends to the Figures

Figure 1. Flow diagram illustrating the process of data collection

Figure 2. Diagram depicting characteristics of selected studies: (A) number of publications per country; (B) number of patients per country; (C) number of publications per severity assessment criterion. The latter (C) indicates the total number of research articles to be 42 instead of 41 because one study reported two populations of patients admitted to the hospital at different periods.

Figure 3. Forest plot of association between COVID-19 severity and (A) platelets; (B) D-dimers.

Figure 4. Forest plots of the association between COVID-19 severity and (A) fibrinogen; (B) activated partial thromboplastin time; (C) prothrombin time.

Figure 5. GOSH diagnostic for influential cases in meta-analysis models (A) PLT; (B) D-dimers.

Figure 6. GOSH plots fixed for influential studies in meta-analysis models (A-B) - fibrinogen; (C-E) - APTT, (F-I) - prothrombin time.

Figure 7. Contour-enhanced funnel plots evaluating the presence of publication bias in the pool of articles that report association between COVID-19 severity and (A) platelets; (B) D-dimers; (C) fibrinogen; (D) activated partial thromboplastin time; (E) prothrombin time.

Legends to Supplementary Materials

Supplementary File 1. Criteria for clinical severity of COVID-19 used by the National Research Center for Cardiac Surgery.

Supplementary Table 1. Results of the NIH Quality Assessment.

Supplementary Table 2. Results of the Egger's test with Pustejovsky's corrected standard error.

Supplementary Figure 1. Exploring influential cases in meta-analysis models with Baujat plots: (A) Platelets, (B) D-dimers, (C) Fibrinogen, (D) Activated partial thromboplastin time, (E) Prothrombin time.

Supplementary Figure 2. Influence diagnostic of meta-analysis model for the association of platelets count and COVID-19 severity.

Supplementary Figure 3. Influence diagnostic of meta-analysis model for the association of D-dimers concentration and COVID-19 severity.

Supplementary Figure 4. Influence diagnostic of meta-analysis model for the association of fibrinogen and COVID-19 severity.

Supplementary Figure 5. Influence diagnostic of meta-analysis model for the association of activated partial thromboplastin time and COVID-19 severity.

Supplementary Figure 6. Influence diagnostic of meta-analysis model for the association of prothrombin time and COVID-19 severity.

Supplementary Figure 7. Search for influential cases by leave-one-out method in meta-analysis models for the association of (A) platelets count, (B) D-dimers and COVID-19 severity.

Supplementary Figure 8. Search for influential cases by leave-one-out method in meta-analysis models for the association of (A) fibrinogen, (B) APTT and COVID-19 severity.

Supplementary Figure 9. Search for influential cases by leave-one-out method in meta-analysis model for the association of prothrombin time and COVID-19 severity.

Supplementary Figure 10. Forest plots of association of COVID-19 severity and (A) platelets count and (B) D-dimers with outliers removed.

Supplementary Figure 11. Forest plots of association of COVID-19 severity and (A) fibrinogen, (B) activated partial thromboplastin time, and (C) prothrombin time with outliers removed.

Supplementary Figure 12. Exploring the influence of meta-analysis study composition on heterogeneity and pooled effect size: (A) fibrinogen, (B) activated partial thromboplastin time, and (C) prothrombin time.

Supplementary Figure 13. Results of three clustering methods (A) K-means, (B) DBSCAN, and (C) Gaussian Mixture on the meta-analysis model for association of fibrinogen and COVID-19 severity.

940 **Supplementary Figure 14.** Results of three clustering methods (A) K-means, (B) DBSCAN,
941 and (C) Gaussian Mixture on the meta-analysis model for association of activated partial
942 thromboplastin time and COVID-19 severity.

943 **Supplementary Figure 15.** Results of three clustering methods (A) K-means, (B) DBSCAN,
944 and (C) Gaussian Mixture on the meta-analysis model for association of prothrombin time
945 and COVID-19 severity.

946 **Supplementary Figure 16.** Exploring presence of publication bias with corrected funnel
947 plots: SMD plotted against sample size-based precision estimate: (A) platelets, (B) D-dimers,
948 (C) fibrinogen, (D) activated partial thromboplastin time, (E) prothrombin time.